3 unknown, 2 completed, 1 active not recruiting, 1 recruiting. 8 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Unknown 3, Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow EC regimen: new trials by email Literature Review of EC regimen trials Research Report on EC regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) - Extensive Stage Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shanghai Henlius Biotech | 200 | 2022-11-18 | 2025-10-21 |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients AL3810, carboplatin + etoposide, Placebo - Extensive-stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Haihe Biopharma Co., Ltd. | 313 | 2019-11-14 | 2020-02-05 |
| Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma Simmtecan, 5-FU and l-LV, Toripalimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder | Phase 2 / Phase 3 | Unknown | Peking University | 336 | 2019-06-19 | 2019-06-20 |
| Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel - Breast Cancer | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 400 | 2009-03-01 | 2016-02-10 |
| Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction Ultrasound, CNB, BCS, Modified Radical Mastectomy - Breast Cancer | Phase 3 | Unknown | Shandong Cancer Hospital and Institute | 4 | 2008-08-01 | 2013-08-06 |
| Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel - Breast Cancer | Phase 3 | Completed | GBG Forschungs GmbH | 2600 | 2007-10-01 | 2016-02-10 |
| Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED) topotecan + cisplatin, Etoposide + carboplatin - Extensive Disease, First-Line | Phase 3 | Terminated | Danish Oncological Lung Cancer Group | 281 | 2006-01-01 | 2016-01-26 |
Breast Neoplasms (3) · Small Cell Lung Carcinoma (3) · Carcinoma, Neuroendocrine (1) · Carcinoma, Small Cell (1) · Lung Neoplasms (1)
GBG Forschungs GmbH (2) · Danish Oncological Lung Cancer Group (1) · Haihe Biopharma Co., Ltd. (1) · Peking University (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Henlius Biotech (1) · SystImmune Inc. (1)
China (3) · Germany (3) · United States (2) · Australia (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Serbia (1)
Gunter von Minckwitz, MD, Prof. (1) · Gunter von Minckwitz, Prof. (1) · Junliang Cai, MD (1) · Lin Shen (1) · Michael Untch, MD, Prof. (1) · Seppo W Langer, MD PhD (1) · Tao Yang, MD (1) · Yong-sheng Wang, MD (1)
PMID 22257523, PMID 22276820, PMID 25223482, PMID 29543566, PMID 29791287, PMID 34037241
2008 (1)